Re: R-E-S-P-E-C-T....
"yeah, I figure we start to climb in Sept. going into ESMO. HCC approval will give us a good bump but the real fireworks will come when some of the cabo/nivo trial data reads out"
Joe, like minds think alike and then every now and then I think like you.... I was just about to post my two cents on a possible explanation for the continued depressed SP despite all the good news and earnings growth. I believe the Cobi trial failure may have hurt EXEL more than we give credit. Not that it would have been a huge revenue generator, but for for the fact that it would have been a second EXEL drug on the market beyond just Cabo. Yes, the expanding indications are good, but still its all with one drug. We only have a single drug right now, subject to a lot of competition, especially the IO therapies. .
But the combination trials with CABO would be I believe a possible game changer, to your point "All revenue projections have been with cabo as a monotherapy. Cabo combined with a checkpoint inhibitor or other immunomodulator could easily double cabo revenue". We could easily establish ourselves as the kinase inhibitor of choice for these IO combos. So I'm in complete agreement; a positive result from any of these trials, may in fact be the one catalyst that unlocks all the risk we are apparently shackled to at the moment as a single monotherapy drug company.
Question: I saw that Memorial Sloan was about to start a trial using Opdivo and Cabo in a combo trial to treat cRCC. Correct me if I'm wrong, but doesn't ther already exist such a trial? And also, when will we see the first read out of any of the Cabo combo trials? Anyone know that?